Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C82697
http://purl.obolibrary.org/obo/NCIT_C82697
|
|---|---|
| Preferred Name | Radgocitabine |
| Definitions |
An analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis. |
|---|---|
| prefLabel | Radgocitabine
|
| label | Radgocitabine
|
| NCI_META_CUI | CL388479
|
| PDQ_Closed_Trial_Search_ID | 633936
|
| code | C82697
|
| Has_Target | |
| prefixIRI | NCIT:C82697
|
| in_subset |
See more
See less
|
| Display_Name | Radgocitabine
|
| Preferred_Name | Radgocitabine
|
| FDA_UNII_Code | 00M634HD2V
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To |
Deoxycytidine Analogue TAS-109
Radgocitabine
|
| CAS_Registry | 135598-68-4
|
| NCI_Drug_Dictionary_ID | 633936
|
| Legacy Concept Name | Deoxycytidine_Analogue_TAS-109
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 633936
|
| Semantic_Type |
Pharmacologic Substance
Nucleic Acid, Nucleoside, or Nucleotide
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |